Update on hepatic intra-arterial chemotherapy

ONCOLOGY

Volumn 11, Issue 7, 1997, Pages 947-957

  Venook, Alan P ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARMUSTINE; DEXAMETHASONE; FLOXURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HEPARIN; IRINOTECAN; MITOMYCIN C; SODIUM CHLORIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; GENE THERAPY; HEPATOBILIARY DISEASE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER METASTASIS; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0030860373     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995 CA Cancer J Clin 45:8-30, 1995.
2. Goslin R, Steele Jr. G, Zamcheck N, et al: Factors influencing survival in patients with hepatic metastases from adenocarcinoma of the colon or rectum. Dis Colon Rectum 25:749-754, 1982.
3. Steele GJ, Bleday R, Mayer RJ, et al: A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 9:1105-1112, 1991.
4. Wanebo HJ, Chu QD, Vezeridis MP, et al: Patient selection for hepatic resection of colorectal metastases. Arch Surg 131:322-329, 1996.
5. Nordlinger B, Guiguet M, Vaillant J-C, et al: Surgical resection of colorectal carcinoma metastases to the liver. Cancer 17:1254-1262, 1996.
6. Brecdis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 30:969-985, 1954.
7. Collins JM Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498-504, 1984.
8. Weiss GR, Garnick MB, Osteen RT, et al Long-term hepatic arterial infusion of 5-fluorodeoxyuridine for liver metastases using an implantable infusion pump. J Clin Oncol 1:337-344, 1983.
9. Balch CM, Urist MM, Soong S-J, et al: A prospective phase II clinical trial of continuous FUDR regional chemotherapy for colorectal metastases to the liver using a totally implantable drug infusion pump. Ann Surg 198:567-573, 1983.
10. Kemeny N, Daly J, Reichman B, et al: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 107(4):459-465, 1987.
11. Hohn DC, Stagg RJ, Friedman MA, et al: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: The Northern Oncology Group Trial. J Clin Oncol 7:1646-1654, 1989.
12. Chang AE, Schneider PD, Sugarbaker PH, et al: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206 685-693, 1987.
13. Martin JK Jr., O'Connell MJ, Wieand HS, et al: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer Arch Surg 125:1022-1027, 1990.
14. Rougier P, Laplanche A, Huguier M, et al: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: Long-term results of a prospective randomized trial J Clin Oncol 10(7):1112-1118, 1992.
15. Allen-Mersh TG, Earlam S, Fordy C, et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344:1255-1260, 1994.
16. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Cancer 78:1639-1645, 1996.
17. Stagg RJ, Venook AP, Chase JL, et al: Alternating hepatic intra-arterial floxuridine and fluorouracil: A less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 83 423-428, 1991.
18. Hohn D, Melnick J, Stagg R, et al: Biliary sclerosis in patients receiving hepatic arterial infusions of floxuridine J Clin Oncol 3:98-102, 1985.
19. Campbell CA, Burns RC, Sitzmann JV, et al. Regional chemotherapy devices: Effect of experience and anatomy on complications. J Clin Oncol 11:822-826, 1993.
20. Hohn DC, Rayner AA, Economou JS, et al: Toxicities and complications of implanted pump hepatic arterial and intravenous floxuridine infusion. Cancer 57:465-470, 1986.
21. Kemeny N, Cohen A, Seiter K, et al: Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer J Clin Oncol 11:330-335, 1993.
22. Hohn DC, Stagg RJ, Price DC, et al: Avoidance of gastroduodenal toxicity in patients receiving hepatic arterial 5-fluoro-2′-deoxyuridine. J Clin Oncol 3(3):1257-1260, 1985.
23. Rayner AA, Kerlan RK, Stagg RJ, et al: Total hepatic arterial perfusion after occlusion of variant lobar vessels: Implications for hepatic arterial chemotherapy. Surgery 99:708-715, 1986.
24. Curley SA, Chase JL, Roll MS, et al: Technical considerations and complications associated with the placement of 180 implantable hepatic arterial infusion devices. Surgery 114:928-935, 1993.
25. Ziessman HA, Thrall JH, Yang PJ, et al: Hepatic arterial perfusion scintigraphy with Tc-99m-MAA Radiology 152:167-172, 1984.
26. Kemeny N, Niedzwiecki D, Shurgot B, et al Prognostic variables in patients with hepatic metastases from colorectal cancer Cancer 63:742-747, 1989.
27. Frye J, Venook A, Ostroff J, et al: Hepatic intra-arterial methylene blue injection during endoscopy: A method of detecting gastroduodenal misperfusion in patients receiving hepatic intra-arterial chemotherapy via an implanted pump. Gastrointest Endosc 38:52-54, 1992.
28. Ludwig J, Kim CH, Wiesner RH, et al: Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 9:215-218, 1989.
29. Kemeny N, Seiter K, Niedzwiecki D, et al: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic cancer. Career 69:327-334, 1992
30. Kemeny N, Seiter K, Conti JA, et al: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. Cancer 73:1134-1142, 1994.
31. Kemeny N, Conti JA, Cohen A, et al: Phase II study of hepatic arterial floxuridine, leucovorin. and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12:2288-2295, 1994.
32. Safi F, Billner R, Roscher R, et al: Regional chemotherapy for hepatic metastases of colorectal carcinoma (continuous intraarrerial versus continuous intraarterial/intravenous therapy. Cancer 64:379-387, 1989.
33. Kemeny N, Conti JA, Sigurdson E, et al: A pilot study of hepatic artery floxuridine combined with systemic 5-fluorouracil and leucovorin. Cancer 71:1964-1971, 1993.
34. Buroker TR, O'Connell MJ, Wieand HS, et al: Randomized companion of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 12:14-20, 1994.
35. Leichman CG, Fleming TR, Muggia FM, et al: Phase II study of fluorouracil and its modu- lation in advanced colorectal cancer: A Southwest Oncology Group study. J Clin Oncol 13:1303-1311, 1995.
36. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovonn in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992.
37. Belluco C, Guillem JG, Kemeny N, et al: p53 nuclear protein overexpression in cotorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14:2696-2701, 1996.
38. Johnston PG, Fisher ER, Rockette HE, et al: The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12:2640-2647, 1994.
39. Cole BF: Evaluating the clinical and economic trade-offs of hepatic arterial infusion. J Natl Cancer Inst 88:222-224, 1996.
40. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of Irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996.
41. Moertel CG, Fleming TR, MacDonald JS, et al: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322:352-358, 1990.
42. Kemeny MM, Goldberg DA, Browning S, et al: Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 55 1265-1270, 1985.
43. Weaver ML, Atkinson D, Zemel R: Hepatic cryosurgery in treating colorectal metastases. Cancer 76:210-214, 1995.
44. Schneebaum S, Walker MJ, Young D, et al: The regional treatment of liver metastases from breast cancer J Surg Oncol 55:26-32, 1994.
45. Atiq OT, Kemeny N, Niedzwiecki D, et al: Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump. Cancer 69:920-924, 1992.
46. Patt YZ, Yoffe B, Charnsangavej C, et al: Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-FU and Interferon-alpha-2b. Cancer 72:2574-2582, 1993
47. Doci R, Bignami P, Bozzetti F, et al: Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 61:1983-1987, 1988
48. Venook AP, Stagg RJ, Lewis BJ, et al: Chemoembolization for hepatocellular carcinoma. J Clin Oncol 8(6):1108-1114, 1990.
49. Groupe d' Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of Lipiodol Chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261, 1995.
50. Mick R, Gupta E, Yokes EE, et al: Limited-sampling models for Irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012-2019, 1996.
51. Wills KN, Maneval DC, Menzel P, et al: Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Human Gene Therapy 5:1079-1088, 1994.